|
...interferon) Australia Zealand. Orphan Australia will initially focus its marketing efforts for Multiferon to target the treatment of high-risk malignant melanoma, as Australia and New Zealand report the highest melanoma incidence rates in the world.
While complete financial terms were not disclosed, the agreement provides Viragen with an up-front license fee, and additional milestone payments to be paid upon receipt of reimbursement authorization for Multiferon in Australia and possibly other countries to be added later. Viragen estimates the agreement to be valued at approximately US$10 - 15 million per year...
NOTE: All illustrations and photos
have been removed from this article.
More articles from BIOTECH Patent News
Merck obtains United States patent., January 01, 2007
BASF obtains United States patent., January 01, 2007
Colorado School of Mines obtains United States patent., January 01, 2007
Chiron obtains United States patent., January 01, 2007
Nastech obtains United States patent., January 01, 2007
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
